Apeptico Forschung und Entwicklung GmbH

About Apeptico

AAPEPTICO, a privately-held biotechnology company located in Austria, develops peptide-based products targeting chronic and life-threatening diseases using its PEPBASE™ discovery technology.

Product portfolio of Apeptico

Product portfolio

Show all

Advanced TFF Technology for Enhanced Monoclonal Antibody Concentration and Processing

Digital membrane chromatography opens up new horizons in protein analysis

High‑Performance Tangential Flow Filtration Solutions for Biopharmaceutical Processing

News about Apeptico

01-Nov-2011 | research and development

APEPTICO Announces Successful Completion of Phase I Trial with AP301 in Oedematous Respiratory Failure

APEPTICO GmbH announced completion of a Phase I clinical trial for its pulmonary sodium ion channel activator AP301. The orally inhaled drug candidate was ...

Read news

13-Apr-2011 | research and development

APEPTICO Initiates Phase I Trial with AP301 in Pulmonary Oedema

APEPTICO, a privately-held biotechnology company developing peptide drugs, announced the initiation of a Phase I clinical trial with its lead product ...

Read news

Show more news about Apeptico

First CO₂ Incubator Shaker with Integrated 180°C Sterilization